Kyntra Bio
KYNB
102 hedge funds and large institutions have $50.4M invested in Kyntra Bio in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 26 increasing their positions, 36 reducing their positions, and 33 closing their positions.
129% more call options, than puts
Call options by funds: $2.02M | Put options by funds: $886K
0.21% less ownership
Funds ownership: 2.48% → 2.27% (-0.21%)
9% less funds holding
Funds holding: 112 → 102 (-10)
24% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 33
28% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 36
65% less capital invested
Capital invested by funds: $146M → $50.4M (-$95.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.46M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.64M |
| 3 |
AC
Armistice Capital
New York
|
+$1.24M |
| 4 |
Goldman Sachs
New York
|
+$1.22M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.63M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.54M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.38M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.19M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.27M |
KYNB Hedge Fund Activity: Q2 2024 in Review
102 of the 6,934 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2024, worth a combined $50.4M — down 65% from $146M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of KYNB and 25 opened new positions — a net loss of 8 holders — while 36 trimmed existing stakes and 26 added.
The largest buyer was Millennium Management, adding an estimated $2.46M. The largest seller was BlackRock, cutting an estimated $5.63M.
- 102 institutional investors held Kyntra Bio (KYNB) as of Q2 2024, down from 112 in Q1 2024.
- Funds reported $50.4M of Kyntra Bio stock for Q2 2024, down 65% quarter-over-quarter.
- 25 funds opened new Kyntra Bio positions in Q2 2024 and 33 closed out, a net change of -8 holders.
- The largest Kyntra Bio buyer in Q2 2024 was Millennium Management, an estimated $2.46M added.
- The largest Kyntra Bio seller in Q2 2024 was BlackRock, an estimated $5.63M sold.
Based on aggregated 13F filings for Q2 2024.